


BIOMARKER TESTING CAN HELP OPTIMIZE TREATMENT OF mNSCLC

IT IS IMPORTANT TO WAIT FOR ALL BIOMARKER TEST RESULTS—
IN ADDITION TO PD-L1—PRIOR TO INITIATING FIRST-LINE THERAPY



More than 60% of all non-squamous mNSCLC patients have **oncogenic drivers**—and of these patients, about 2 in 3 have an actionable biomarker.^{1-5*}



Targeted therapies may lead to better outcomes in patients with actionable biomarkers.⁶⁻⁹

- Conversely, some **biomarker-driven cancers may respond poorly to less-targeted options like immunotherapy (IO)**—these patients are often excluded from IO clinical trials^{10,11}
- Starting patients on IO and **switching to a targeted therapy may lead to increased risk for immune-related adverse events**^{12,13}



Across all PD-L1 expression levels, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®]) recommend patients are **negative for actionable molecular markers before utilizing IO** as a first-line treatment option for mNSCLC.^{14†}

*Regardless of PD-L1 expression.

See the NCCN Guidelines[®] for NSCLC for detailed recommendations, including preferred treatment options. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

†The NCCN Guidelines[®] for NSCLC provide recommendations for certain individual biomarkers that should be tested and recommend testing techniques, but do not endorse any specific commercially available biomarker assays or commercial laboratories.

mNSCLC=metastatic non-small cell lung cancer; NCCN[®]=National Comprehensive Cancer Network[®]; PD-L1=programmed death-ligand 1.


Learn more about how waiting for all the biomarker results can help you develop a more optimized treatment plan at [biomarkertesting.com](https://www.biomarkertesting.com)

UNDERSTANDING THE BENEFIT OF COMPREHENSIVE BIOMARKER TESTING

By using a broad panel-based approach, like next-generation sequencing (NGS), you could improve the overall patient experience and make biomarker testing more efficient versus sequential single-gene testing¹⁵:



Account for multiple biomarkers with one test



Fewer rebiopsies and complications



Shorter time-to-test results



Lower costs to healthcare system

NCCN Guidelines® recommendations for biomarker testing in NSCLC¹⁴

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend:

Molecular testing be performed (when feasible) via a broad panel-based approach, typically by NGS, for patients with mNSCLC.

Upfront PD-L1 expression testing before first-line therapy in patients with mNSCLC.

mNSCLC=metastatic non-small cell lung cancer; NCCN®=National Comprehensive Cancer Network®; PD-L1=programmed death-ligand 1.

Want to learn more?

Go to biomarkertesting.com/contact to reach out to your local representative.

References: **1.** Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments. *Lancet*. 2017;389(10066):299-311. **2.** VanderLaan PA, Rangachari D, Costa DB. The rapidly evolving landscape of biomarker testing in non-small cell lung cancer. *Cancer Cytopathol*. 2021;129(3):179-181. **3.** US Food and Drug Administration. <https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-sotorasib-kras-g12c-mutated-nsclc>. Accessed June 10, 2021. **4.** König D, Prince SS, Rothschild SI. Targeted therapy in advanced and metastatic non-small cell lung cancer. An update on treatment of the most important actionable oncogenic driver alterations. *Cancers (Basel)*. 2021;13(4):804. **5.** Peters S, Reck M, Smit EF, Mok T, Hellmann MD. How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer. *Ann Oncol*. 2019;30(6):884-896. **6.** Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. *JAMA*. 2014;311(19):1998-2006. **7.** Barlesi F, Mazières J, Merlio JP, et al. Routine molecular profiling of cancer: results of a one-year nationwide program of the French Cooperative Thoracic Intergroup (IFCT) for advanced non-small cell lung cancer (NSCLC) patients. *Lancet*. 2016;287(10026):1415-1426. **8.** Solomon BJ, Kim D-W, Wu Y-L, et al. *J Clin Oncol*. 2018;36(22):2251-2258. **9.** Gutierrez ME, Choi K, Lanman RB, et al. Genomic profiling of advanced non-small cell lung cancer in community settings: gaps and opportunities. *Clin Lung Cancer*. 2017;18(6):651-659. **10.** Offin M, Guo R, Wu SL, et al. Immunophenotype and response to immunotherapy of RET-rearranged lung cancers. *JCO Precis Oncol*. 2019;3(10):1-8. **11.** Lisberg A, Cummings A, Goldman JW, et al. *J Thorac Oncol*. 2018;13(8):1138-1145. **12.** Lin JJ, Chin E, Yeap BY, et al. *J Thorac Oncol*. 2019;14(1):135-140. **13.** Schoenfeld AJ, Arbour KC, Rizvi H, et al. *Ann Oncol*. 2019;30(5):839-844. **14.** Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V.5.2021. ©National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed June 25, 2021. To view the most recent and complete version of the guideline, go online to [NCCN.org](https://www.nccn.org). **15.** Pennell NA, Mutebi A, Zhou Z-Y, et al. Economic impact of next-generation sequencing versus single-gene testing to detect genomic alterations in metastatic non-small-cell lung cancer using a decision analytic model. *JCO Precis Oncol*. 2019;3:1-9.